Transaction Date | Company Name | Insider Name (Title) | Activity | Stock | Acquired or Disposed | Shares | Price range | Amount |
---|---|---|---|---|---|---|---|---|
2024-04-15 | CRISPR Therapeutics AG | Kulkarni Samarth
(Chief Executive Officer) |
S | Common Shares | D | 19582 | $59.88 - $60.40 | $1,173,230 |
2024-04-15 | CRISPR Therapeutics AG | Kulkarni Samarth
(Chief Executive Officer) |
M | Common Shares | A | 19582 | $19.12 - $19.12 | $374,407 |
2024-03-15 | CRISPR Therapeutics AG | Prasad Raju
(Chief Financial Officer) |
S | Common Shares | D | 3524 | $72.69 - $72.69 | $256,159 |
2024-03-15 | CRISPR Therapeutics AG | Kulkarni Samarth
(Chief Executive Officer) |
S | Common Shares | D | 20000 | $71.97 - $73.06 | $1,449,627 |
2024-03-15 | CRISPR Therapeutics AG | Kulkarni Samarth
(Chief Executive Officer) |
M | Common Shares | A | 20000 | $19.12 - $19.12 | $382,400 |
2024-03-11 | CRISPR Therapeutics AG | KASINGER JAMES R.
(General Counsel and Secretary) |
S | Common Shares | D | 3947 | $74.44 - $78.26 | $304,514 |
2024-03-11 | CRISPR Therapeutics AG | Kulkarni Samarth
(Chief Executive Officer) |
S | Common Shares | D | 14385 | $74.44 - $78.26 | $1,108,262 |
2024-02-27 | CRISPR Therapeutics AG | George Simeon
(Director) |
A | Common Shares | A | 1048951 | $71.50 - $71.50 | $74,999,996 |
2024-02-20 | CRISPR Therapeutics AG | KASINGER JAMES R.
(General Counsel and Secretary) |
S | Common Shares | D | 1913 | $79.67 - $79.67 | $152,408 |
2024-02-20 | CRISPR Therapeutics AG | Kulkarni Samarth
(Chief Executive Officer) |
S | Common Shares | D | 6370 | $79.67 - $79.67 | $507,497 |
2024-02-15 | CRISPR Therapeutics AG | Kulkarni Samarth
(Chief Executive Officer) |
S | Common Shares | D | 20000 | $79.94 - $81.66 | $1,607,175 |
2024-02-15 | CRISPR Therapeutics AG | Kulkarni Samarth
(Chief Executive Officer) |
M | Common Shares | A | 20000 | $19.12 - $19.12 | $382,400 |
2024-01-29 | CRISPR Therapeutics AG | Kulkarni Samarth
(Chief Executive Officer) |
S | Common Shares | D | 50000 | $60.50 - $61.10 | $3,025,571 |
2024-01-29 | CRISPR Therapeutics AG | Kulkarni Samarth
(Chief Executive Officer) |
M | Common Shares | A | 50000 | $19.12 - $19.12 | $956,000 |
2024-01-16 | CRISPR Therapeutics AG | Kulkarni Samarth
(Chief Executive Officer) |
S | Common Shares | D | 20000 | $62.50 - $62.50 | $1,250,058 |
2024-01-16 | CRISPR Therapeutics AG | Kulkarni Samarth
(Chief Executive Officer) |
M | Common Shares | A | 20000 | $19.12 - $19.12 | $382,400 |
A | Grant, award or other acquisition |
C | Conversion of Derivative or Security |
D | Disposition to the issuer of issuer equity securities |
E | Expiration of short derivative position |
F | Payment of exercise price or tax liability |
G | Bona fide Gift |
H | Expiration (or cancellation) of long derivative position with value received |
I | Discretionary Transaction |
J | Other acquisition or disposition |
K | Transaction in equity swap or instrument with similar characteristics |
L | Small Acquisition |
M | Exercise or conversion of derivative security |
O | Exercise of out-of-the-money derivative security |
P | Open Market Purchase |
S | Open Market Sale |
U | Disposition pursuant to a tender of shares in a change of control transaction |
V | Transaction Voluntarily Reported |
X | Exercise of in-the-money or at-the-money derivative security |
Z | Deposit into or withdrawal from voting trust |